Shanlian Hu
Overview
Explore the profile of Shanlian Hu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
1113
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tan B, Lin A, Han R, Bai L, Sun J, Hu S, et al.
Adv Ther
. 2025 Feb;
PMID: 40016439
Introduction: This study aimed to establish and apply a multicriteria value framework to determine the value of prophylaxis versus on‑demand treatment in adult patients with hemophilia A in China, which...
2.
Rasooly A, Pan Y, Tang Z, He J, Shao R, Ellen M, et al.
Int J Health Policy Manag
. 2024 Aug;
13:8491.
PMID: 39099497
No abstract available.
3.
Jia Y, Qiao X, Zhao J, Li H, Hu S, Hu M
Neurosci Bull
. 2023 Nov;
40(4):533-538.
PMID: 37917312
No abstract available.
4.
Hu S, Wu D, Wu J, Zhang Y, Bogelund M, Pohlmann J, et al.
Patient Relat Outcome Meas
. 2023 Oct;
14:253-267.
PMID: 37789883
Purpose: Treatment process attributes can affect health state utilities associated with therapy. For intravenous iron, used to treat iron deficiency and iron deficiency anemia, research into process attributes is still...
5.
6.
Hu S, Tang Z, Harrison J, Hertel N, Penrod J, May J, et al.
Pharmacoecon Open
. 2023 Mar;
7(2):273-284.
PMID: 36897427
Objective: To evaluate the economic value of nivolumab versus docetaxel for advanced non-small cell lung cancer (aNSCLC) treatment after platinum-based chemotherapy in adults without epidermal growth factor receptor/anaplastic lymphoma kinase...
7.
Tang M, Zhang X, Ye Z, Feng L, Yang Y, Hou Z, et al.
Biosci Trends
. 2023 Feb;
17(1):1-13.
PMID: 36775343
A hospital-based health technology assessment (HB-HTA) can provide the evidence needed to inform clinical decisions at the administrative level. With the implementation of a new round of medical and health...
8.
Ming J, Wu Y, Han R, Xu X, Waldeck R, Hu S
Adv Ther
. 2023 Jan;
40(3):1087-1103.
PMID: 36630046
Introduction: The increasing incidence of prostate cancer (PC) in China leads to a significant disease burden. Although three novel androgen inhibitors (darolutamide, apalutamide, and enzalutamide) have been approved for patients...
9.
Rasooly A, Pan Y, Tang Z, Jiangjiang H, Ellen M, Manor O, et al.
Int J Health Policy Manag
. 2022 Aug;
11(12):3019-3031.
PMID: 35942954
Background: Quality measurements in primary healthcare (PHC) have become an essential component for improving diabetes outcomes in many high-income countries. However, little is known about their implementation within the Chinese...
10.
Chen R, Gultyaev D, Lister J, Han R, Hu N, Malacan J, et al.
BMC Med Res Methodol
. 2022 Aug;
22(1):215.
PMID: 35931967
Background: Long-term prophylactic therapy is considered the standard of care for hemophilia A patients. This study models the long-term clinical and cost outcomes of two factor VIII (FVIII) products using...